FDA Awards Orphan Drug Designation to Mesothelioma Treatment

Article

Nintedanib combination shows significant clinical benefit treating mesothelioma

Boehringer Ingelheim has announced that the FDA has granted orphan drug designation to nintedanib, a triple angiokinase inhibitor, for the treatment of mesothelioma.

The company revealed results from its LUME-Meso phase 2 trial at the beginning of December, which showed how nintedanib (with pemetrexed/cisplatin) could affect patients with unresectable malignant pleural mesothelioma (MPM). The researchers concluded that nintedanib, in combination with pemetrexed/cisplatin, demonstrated a significant clinical benefit compared to a placebo.

The most common adverse effects associated with nintedanib were neutropenia, elevated liver enzymes, and an increase in gamma glutamyltransferase.

"Nintedanib, our triple angiokinase inhibitor, has shown promise as a potential treatment for malignant pleural mesothelioma in clinical trials to-date, and this designation is a validating milestone in its development," Martina Flammer, MD, Vice President of Clinical Development & Medical Affairs Specialty Care at Boehringer Ingelheim, said in a press release. "

The company is now recruiting participants for its next study on nintedanib. The phase 2/3 trial will evaluate the safety and efficacy of nintedanib in combination with pemetrexed/cisplatin, and nintedanib with pemetrexed/cisplatin, followed by a placebo.

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Aimee Keegan, PharmD, BCOP, a clinical pharmacist
© 2024 MJH Life Sciences

All rights reserved.